» Articles » PMID: 27630567

The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats

Overview
Journal Front Pharmacol
Date 2016 Sep 16
PMID 27630567
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of patients with terminal breast cancer show signs of bone metastasis, the most common cause of pain in cancer. Clinically available drug treatment options for the relief of cancer-associated bone pain are limited due to either inadequate pain relief and/or dose-limiting side-effects. One of the major hurdles in understanding the mechanism by which breast cancer causes pain after metastasis to the bones is the lack of suitable preclinical models. Until the late twentieth century, all animal models of cancer induced bone pain involved systemic injection of cancer cells into animals, which caused severe deterioration of animal health due to widespread metastasis. In this mini-review we have discussed details of a recently developed and highly efficient preclinical model of breast cancer induced bone pain: Walker 256 cancer cell- induced bone pain in rats. The model involves direct localized injection of cancer cells into a single tibia in rats, which avoids widespread metastasis of cancer cells and hence animals maintain good health throughout the experimental period. This model closely mimics the human pathophysiology of breast cancer induced bone pain and has great potential to aid in the process of drug discovery for treating this intractable pain condition.

Citing Articles

Mesenchymal stem cell transplantation plays a role in relieving cancer pain.

Zhang W, Chen D Front Pharmacol. 2024; 15:1483716.

PMID: 39679363 PMC: 11637888. DOI: 10.3389/fphar.2024.1483716.


N4-acetylcytidine acetylation of neurexin 2 in the spinal dorsal horn regulates hypersensitivity in a rat model of cancer-induced bone pain.

Xu L, Zheng S, Chen L, Yang L, Zhang S, Liu B Mol Ther Nucleic Acids. 2024; 35(2):102200.

PMID: 38831898 PMC: 11145350. DOI: 10.1016/j.omtn.2024.102200.


Characterization and antitumor effect of doxorubicin-loaded FeO-Au nanocomposite synthesized by electron beam evaporation for magnetic nanotheranostics.

Orel V, Kurapov Y, Lytvyn S, Orel V, Galkin O, Dasyukevich O RSC Adv. 2024; 14(20):14126-14138.

PMID: 38686287 PMC: 11056945. DOI: 10.1039/d4ra01777c.


Behavioral Voluntary and Social Bioassays Enabling Identification of Complex and Sex-Dependent Pain-(-Related) Phenotypes in Rats with Bone Cancer.

Segelcke D, Linnemann J, Pradier B, Kronenberg D, Stange R, Richter S Cancers (Basel). 2023; 15(5).

PMID: 36900357 PMC: 10000428. DOI: 10.3390/cancers15051565.


-Elemene Improves Morphine Tolerance in Bone Cancer Pain via N-Methyl-D-Aspartate Receptor 2B Subunit-Mediated -Opioid Receptor.

Zhou Q, Gong L, Bao G, Ding Q, Ji J Comput Math Methods Med. 2022; 2022:9897669.

PMID: 36164617 PMC: 9509249. DOI: 10.1155/2022/9897669.


References
1.
Koltzenburg M, WALL P, McMahon S . Does the right side know what the left is doing?. Trends Neurosci. 1999; 22(3):122-7. DOI: 10.1016/s0166-2236(98)01302-2. View

2.
Walker K, Fox A, Urban L . Animal models for pain research. Mol Med Today. 1999; 5(7):319-21. DOI: 10.1016/s1357-4310(99)01493-8. View

3.
Rees R, Mian S . Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother. 1999; 48(7):374-81. PMC: 11037132. DOI: 10.1007/s002620050589. View

4.
Schwei M, Honore P, Rogers S, Salak-Johnson J, Finke M, Ramnaraine M . Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999; 19(24):10886-97. PMC: 6784931. View

5.
Kurth A, Kim S, SEDLMEYER I, Hovy L, Bauss F . Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br. 2000; 82(1):126-30. DOI: 10.1302/0301-620x.82b1.9483. View